Skip to main content
Premium Trial:

Request an Annual Quote

NCI Commits $10M in SBIR Funding for Projects Including Proteomics Reagent Development

Premium

The National Cancer Institute's Small Business Innovation Research Development Center this week announced $10 million in new contract funding opportunities, including several for proteomics research reagents.

Specifically, NCI called for proposals for technology to generate anti-peptide affinity agents for proteomic studies using techniques such as SISCAPA.

Development of the reagents is to be done in coordination with the NCI's Clinical Proteomic Technologies for Cancer initiative. In the first phase of the contract, which is budgeted for $200,000 and nine months, awardees will be expected to develop high-affinity, high-specificity reagents against 10 different peptides. In the second phase, which is budgeted for $1 million and two years, awardees are expected to develop at least 100 anti-peptide capture agents in coordination with the CPTC and work to integrate them into proteomic research platforms.

Funding is also available for the development of human tissue culture systems mimicking the tumor microenvironment; development of standards for metabolomics research; and development of chemically defined glycan libraries for reference standards and glycomics research.

Applications are due by Nov. 13.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.